Tien Liang BioTech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023
Share
Tien Liang BioTech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 108.31 million compared to TWD 121.62 million a year ago. Net loss was TWD 1.44 million compared to net income of TWD 9.06 million a year ago. Basic loss per share from continuing operations was TWD 0.03 compared to basic earnings per share from continuing operations of TWD 0.2 a year ago. Diluted loss per share from continuing operations was TWD 0.03 compared to diluted earnings per share from continuing operations of TWD 0.2 a year ago.
For the nine months, sales was TWD 343.38 million compared to TWD 394.74 million a year ago. Net income was TWD 10.52 million compared to TWD 44.02 million a year ago. Basic earnings per share from continuing operations was TWD 0.23 compared to TWD 0.96 a year ago. Diluted earnings per share from continuing operations was TWD 0.23 compared to TWD 0.96 a year ago.
Tien Liang BioTech Co., Ltd. is a Taiwan-based company principally engaged in the manufacture, wholesale and retail of health food products. The Company is also involved in the import, wholesale and retail of western medicines, as well as the manufacture and sales of traditional Chinese medicines. The Company also provides active pharmaceutical ingredients (APIs), biopharmaceuticals and others. The Company distributes its products in domestic market.